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ABSTRACT
Introduction: We evaluated the diagnostic
reliability of serum polymerase chain reaction
(PCR) versus blood culture, abdominal fluid or
both (composite measure) in patients receiving
empirical antifungal treatment for suspected
invasive candidiasis.
Methods: This observational, prospective, non-
interventional, multicentre study in Spain
enrolled 176 critically ill patients admitted to
the intensive care unit. Separate blood samples
for culture and serum PCR were taken before the
start of antifungal therapy. Patient assessment
was performed according to each site’s usual
clinical practice. The primary end point was
concordance between serum PCR and blood
culture. Secondary end points were concor-
dance between serum PCR and a positive
abdominal fluid sample or the composite mea-
sure. Quality indices included sensitivity,
specificity, positive/negative predictive values
(PPV/NPV) and kappa indices.
Results: Among 175 evaluable patients, rates of
Candida detection were similar for serum PCR
(n = 16/175, 9.1%) versus blood culture (n = 14/
175, 8.0%). Quality indices for serum PCR rela-
tive to blood culture were: sensitivity 21.4%;
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specificity 91.9%; PPV 18.8%; NPV 93.1%;
kappa index 0.125. Thirty-two abdominal fluid
samples were positive. Quality indices for serum
PCR versus abdominal fluid were: sensitivity
31.3%; specificity 83.0%; PPV 15.6%; NPV
92.3%; kappa index 0.100. Quality indices for
serum PCR versus the composite measure were:
sensitivity 15.8%; specificity 92.7%; PPV 37.5%;
NPV 79.9%; kappa index 0.107.
Conclusion: The sensitivity of serum PCR for
Candida detection was low and the rate of
concordance was low between serum PCR and
the other diagnostic techniques used to identify
Candida infections. Hospital-based diagnostic
tests need optimising to improve outcomes in
patients with suspected invasive candidiasis.
Funding: Astellas Pharma Inc.
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INTRODUCTION
Candida species are among the top ten blood-
stream pathogens [1] and remain the most
common cause of invasive fungal infections
worldwide [2–5]. There is wide inter-regional
variability in the incidence of blood infections
due to Candida spp. (candidaemia). One review
suggests the incidence may vary between 1.2
and 25 cases per 100,000 inhabitants [6]. Inva-
sive candidiasis, which occurs when Candida
spp. infects other tissues and organs, causes
significant morbidity and high mortality rates
[1, 7–9]. Furthermore, the costs associated with
invasive candidiasis are substantial because of
the need to use additional diagnostic proce-
dures, prolonged hospitalisation and extra
medications [10–12].
Patients with haematological malignancies
or neutropenia, those undergoing gastroin-
testinal surgery, premature infants or patients
aged[70 years are at increased risk for acquir-
ing candidaemia during hospitalisation due to
an underlying medical condition [13]. Within
these high-risk groups, specific factors further
increase the risk for invasive candidiasis, for
instance, surgery, the presence of vascular
catheters, mucosal colonisation with Candida
spp., sepsis, length of previous antibiotic ther-
apy and receipt of total parenteral nutrition
[13–20]. These risk factors are frequently
encountered in critically ill patients in the
intensive care unit (ICU) [21] where the inci-
dence of candidaemia is tenfold higher com-
pared with other hospital wards, and mortality
rates are between 25 and 50% [22–25].
The difficulties in obtaining an early and
accurate diagnosis of invasive candidiasis in
critically ill patients have led to the widespread
use of empirical antifungal treatment in such
patients [25–27]. Empirical antifungal treat-
ment in high-risk patients is currently recom-
mended by the European Society for Clinical
Microbiology and Infectious Diseases [28] as
well as by the Infectious Diseases Society of
America [29]. There is moderate-quality evi-
dence showing that empirical antifungal ther-
apy with an echinocandin can be effective in
high-risk settings; therefore, the echinocandins
are strongly recommended for empiric treat-
ment in non-neutropenic patients with sus-
pected invasive candidiasis within an ICU
setting [30]. However, this strategy may con-
tribute to the overuse of antifungals and could
increase the risk of antifungal resistance, which
may have implications for the length of hospi-
tal stay, lead to adverse patient outcomes and
potentially increase healthcare costs [9, 31, 32].
Blood culture is the current ‘gold’ standard
for diagnosing invasive candidiasis, despite its
numerous limitations, which include delays of
up to 48 h until results are available for the
majority of patients [33, 34] and possibly longer
when information on specific species is required
[35]. As it has been shown that delays in initi-
ating appropriate treatment significantly
increase the all-cause mortality rate, indepen-
dently of other risk factors [33, 34], a prompt
and accurate diagnosis of invasive candidiasis is
crucially important. In addition, blood cultures
show positivity in only a minority of cases
(especially in patients with deep-seated can-
didiasis) and often only late during the course
of infection [1].
To overcome these difficulties, polymerase
chain reaction (PCR)-based assays have been
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introduced as an alternative tool for diagnosing
invasive candidiasis [25]. The advantages of PCR
testing include same-day identification of Can-
dida spp. and the potential for relatively fast and
continuous monitoring of persistence or reso-
lution of infection [36]. A comprehensive sys-
tematic review and meta-analysis of PCR
diagnosis for invasive candidiasis has been
conducted: 54 studies comprising 4694 patients
(of whom 963 had proven, probable or possible
invasive candidiasis) were included. The results
from this meta-analysis demonstrated that PCR
can have a higher diagnostic sensitivity than
blood culture, with pooled sensitivity and
specificity values of 95% and 92%, respectively.
Importantly, PCR allowed the earlier diagnosis
of Candida infections [36].
The aims of the current study were to eval-
uate the diagnostic reliability of serum PCR
versus either blood culture or abdominal fluid
samples (and both as a composite measure) and
to assess the clinical response to antifungal
therapy in critically ill patients with suspected
invasive candidiasis admitted to ICUs across
Spain.
METHODS
Study Design and Population
This was a prospective, multicentre, observa-
tional, non-interventional study (Astellas study
no. AST-INF-2012-01) conducted in 27 centres
and 9 regions across Spain. The date of first
enrolment was 18 March 2013 and the last
evaluation was completed on 2 January 2015.
An Independent Ethics Committee or an Insti-
tutional Review Board reviewed and approved
the protocol, protocol amendments and patient
information before the start of the study. The
‘‘master’’ ethics committee was the H. Clinico
San Carlos committee (a list of all ethics
approval bodies that approved the study in the
various centres is included in the supplemen-
tary material). The study was conducted in
accordance with the principles of the 1964
Declaration of Helsinki and its later amend-
ments, Good Clinical Practice guidelines and
International Conference on Harmonisation
guidelines. Informed consent was provided by
all patients, or their legal representative, before
the start of the study.
Inclusion criteria were male or female
patients aged C 18 years admitted to the ICU
and requiring empirical antifungal therapy
because of a high risk of invasive candidiasis.
Patients meeting at least one of the following
criteria were considered at high risk: those with
a Candida score C 3 (based on severe sepsis, 2
points; surgery, 1 point; parenteral nutrition, 1
point; Candida at multiple sites of infection, 1
point); patients with sepsis and C 3 risk factors
for invasive candidiasis (from severe pancreati-
tis, extra-renal depuration, broad-spectrum
antibiotic treatment for [ 7 days, abdominal
surgery, ICU stay of [ 15 days, parenteral
nutrition, central venous catheterisation, Can-
dida at multiple sites of infection, candiduria
and Acute Physiology and Chronic Health
Evaluation score[15); or immunocompro-
mised patients with sepsis. Patients with docu-
mented candidiasis at enrolment, patients
taking antifungals at the time of screening or
those with any condition that, in the opinion of
the investigator, rendered their participation
inadvisable were excluded from enrolment.
Treatment and Response Criteria
This was a non-interventional study. Patients
were recruited consecutively and managed and
treated according to the physicians’ usual clin-
ical practice. The decision to prescribe antifun-
gal therapy was made prior to (and
independently from) the patient’s inclusion in
the study. Once the decision had been made to
initiate treatment, patients were recruited into
the study and the pertinent data and samples
were collected at enrolment prior to initiating
antifungal treatment, which was then admin-
istered according to the physicians’ usual
practice.
Any other treatments that the patients could
receive were according to the treating physi-
cian’s regular clinical practice and each site’s
health care protocols.
Investigators were asked to make a clinical
assessment of the clinical and microbiological
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response to empirical antifungal treatment for
the suspected invasive candidiasis.
Microbiological Analyses
Microbiological analyses are summarised in
Fig. 1. A blood sample (C 10 ml) for culture and
serum PCR was taken by peripheral venepunc-
ture, before the first dose of antifungal therapy.
Follow-up blood samples for culture and serum
PCR were taken according to the site’s usual
clinical practice/guideline recommendations 3
and 7 days after the baseline sample. Blood
sample collection and management were stan-
dardised across the study centres. Samples for
PCR were sent to the National Microbiology
Centre (CNM).
Blood cultures were processed within each
site’s microbiology department, according to
Fig. 1 Microbiological analyses. *Patients meeting the
following criteria were considered at high risk: those with
a Candida score C 3 (based on severe sepsis, 2 points;
surgery, 1 point; parenteral nutrition, 1 point; Candida at
multiple sites of infection, 1 point); patients with sepsis
and C 3 risk factors for invasive candidiasis (from severe
acute pancreatitis, extra-renal depuration, broad-spectrum
antibiotic treatment for [ 7 days, major abdominal
surgery, ICU stay of [ 15 days, parenteral nutrition,
central venous catheterisation, Candida at multiple sites of
infection, candiduria and Acute Physiology and Chronic
Health Evaluation score [ 15); or sepsis in
immunocompromised patients with neutropenia, haema-
tological disease, solid organ or bone marrow transplanta-
tion, treatment with immunosuppressive drugs,
chemotherapy or monoclonal antibodies; or human
immunodeficiency virus infection. **Blood sample times
were as follows: at baseline (before initiating antifungal
treatment) and at follow-up (blood cultures were taken
according to the site’s usual clinical practice). Serum PCR
was performed at the same time as the blood culture
sample. ICU intensive care unit, MALDI-TOF matrix-
assisted laser desorption/ionisation time of flight, PCR
polymerase chain reaction
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usual hospital practice, with identification of
isolated strains. When a Candida spp. was iso-
lated, identification and sensitivity tests were
performed within each site, according to a
standardised protocol. The original blood sam-
ples were then frozen and sent to the Reference
Centre (National Microbiology Centre, Hospital
Clı´nico San Carlos) to confirm the initial iden-
tification and sensitivity results. At the Refer-
ence Centre, Candida isolates were identified,
and the sensitivity results determined by the
minimum inhibitory concentration to antifun-
gal therapy were confirmed by conventional
testing, with the original sample used to con-
firm identification by matrix-assisted laser des-
orption/ionisation time-of-flight mass
spectrometry.
The remainder of the blood sample used for
the PCR assay was centrifuged at 3000 rpm for
10 min to separate the serum, which was then
frozen at - 20 C. The frozen serum samples
were stored at each site’s microbiology depart-
ment until they were sent to the Reference
Centre. All the samples were identified by
specifically designed labels, and the sites also
had specially designed data sheets for accurate
sample matching and identification.
Abdominal fluid samples were obtained from
the peritoneal cavity during laparotomy or from
peritoneal drainage catheters (placed within
24 h of surgery) and were cultured according to
each site’s regular clinical practice and sub-
jected to sensitivity testing. When Candida spp.
were identified, isolates were sent to the Refer-
ence Centre to confirm the initial identification
and sensitivity results by conventional testing.
Multiplex Real-Time PCR Assay
Deoxyribonucleic acid (DNA) for PCR assays
was extracted from blood and sera using the
QIAamp DNA Mini kit (Qiagen, Izasa, Madrid,
Spain), following the manufacturer’s instruc-
tions. DNA was eluted in 50 ll of buffer, and
2.2 ll of DNA extracted from each sample was
used for subsequent PCR. Two multiplex PCR
assays, developed by Fortun et al. (2014), were
used to detect six Candida species common in
IC (Candida albicans, C. parapsilosis, C. tropicalis,
C. glabrata, C. krusei, and C. guilliermondii); these
PCR assays have been described in detail else-
where [25]. Briefly, Candida spp. were detected
using molecular probes with fluorescent dyes
(FAM, HEX, ROX, and CYAN 500). Probes and
primers were designed based on the ITS1/2
sequences of ribosomal DNA regions of Candida
strains belonging to the Spanish National Cen-
ter of Microbiology collection, using Beacon
Designer 5.0 software (Premier Biosoft, Palo
Alto, CA, USA). Two multiplex PCRs were per-
formed simultaneously in the LightCycler 480
system (Roche Diagnostics, Mannheim, Ger-
many), one using the LightCycler Probes Master
Kit (Roche Diagnostic, Madrid, Spain) to detect
C. albicans, C. parapsilosis and C. tropicalis and
one using the 2 9 Sensimix Probe Kit (Quan-
tace, Ecogen, Madrid, Spain) to detect C. glab-
rata, C. krusei and C. guilliermondii. Samples were
analysed in duplicate and standards were run
with each set of samples and negative controls.
The following CT values were used to define a
positive PCR result: C. albicans (20 fg DNA)
34.15–37.44; C. parapsilosis (20 fg DNA)
31.45–35.39; C. tropicalis (20 fg DNA)
32.34–36.16; C. glabrata (200 fg DNA)
31.10–36.24; C. krusei (20 fg DNA) 34–38 (200 fg
DNA) 30.80–33.80; C. guilliermondii (20 fg DNA)
38.40–42.31. The overall result was considered
positive if both PCRs for each sample were
positive according to the laboratory standard.
Sensitivity was determined at the Reference
Centre; isolates were identified and the sensi-
tivity results, determined by the minimum
inhibitory concentration of Candida isolates to
antifungal therapy, were confirmed by conven-
tional testing.
Those who conducted the blood/abdominal
fluid tests were blinded to the results of the PCR
analyses, and vice versa.
A diagnosis of invasive candidiasis was made
when a positive blood culture or positive
abdominal fluid sample was obtained from a
surgical setting or a peritoneal drainage catheter
(placed within 24 h of surgery) or when a posi-
tive PCR was recorded in samples from patients
whose clinical condition improved with anti-
fungal treatment.
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End Points
The primary end point was the degree of con-
cordance between the results of the serum PCR
and blood culture. Secondary end points were
the degree of concordance between the results
for serum PCR and a positive abdominal fluid
culture and positivity for blood culture or
abdominal fluid culture (assessed as a composite
measure).
The relationship between the presence of
invasive candidiasis and the risk factors that
contribute to a patient’s high-risk status (Can-
dida score C 3; sepsis and C 3 risk factors for
invasive candidiasis; sepsis and immunosup-
pression) was also investigated.
Data were collected from all patients at the
time of enrolment and, if available, when fol-
low-up blood cultures were performed, on dis-
charge from the ICU and at the end of
antifungal treatment.
Statistical Analysis
The sample size was calculated based on the
primary end point using estimates of the sensi-
tivity of serum PCR (80%) and blood culture
(50%), based on the published literature
[35, 37], and the kappa index of concordance
between both techniques (0.3) in patients with
suspected invasive candidiasis, admitted to
ICUs in which empirical treatment was initiated
with an antifungal. Taking these estimates into
account, a sample size of 179 patients would
provide precision of ± 0.1 to estimate concor-
dance between serum PCR and blood culture
diagnoses, with 95% confidence intervals (CIs).
Using the assumption that 10% of patients
would not be eligible, the planned sample size
was 199. The sample size calculation was per-
formed using EpiData software, version 3.1 (The
EpiData Association, Odense, Denmark).
The analysis population included all patients
who fulfilled the entry criteria and were con-
sidered evaluable. Concordance between the
results of serum PCR and blood culture (primary
end point) was assessed by estimating the kappa
index. The kappa index, which assesses inter-
test reliability, can range from - 1 to ? 1, with
higher scores indicating greater concordance
[38].
The sensitivity, specificity, positive predic-
tive value (PPV) and negative predictive value
(NPV) and the respective 95% CIs were calcu-
lated for serum PCR relative to blood culture.
Positive and negative odds ratios (ORs) and
post-test probabilities [positive post-test proba-
bility (PPTP) and negative post-test probability
(NPTP)] were also determined.
Concordance between the results of serum
PCR versus abdominal fluid culture and versus
the composite measure were analysed in the
same way as the primary end point. The rela-
tionship between the presence of invasive can-
didiasis and patient risk factors (Candida
score C 3; sepsis and C 3 risk factors for invasive
candidiasis; sepsis and immune suppression)
was analysed using a Chi-squared test. Binary
logistic regression models were used to deter-
mine which risk factors had the greatest weight,
according to the microbiological test used.
These models were executed hierarchically and
with the stepwise backward method. Data were
presented as ORs and 95% CIs.
An adjusted binary logistic regression model
(with a bilateral significance level of 0.10, Chi-
squared test) was used to evaluate which of the
individual risk factors were related to the pres-
ence of invasive candidiasis according to blood
culture results. All calculations were performed
with STATA for Windows, version 12 (http://
www.stata.com/).
RESULTS
Patient Population
Overall, 176 patients were recruited into the
study; of these, 175 patients were regarded as
evaluable and included in the analysis set.
Of the total evaluable patients, 125 (71.4%)
completed the study period and 50 (28.6%)
withdrew early. Among the patients who with-
drew early, 37 died (21.1% of the total evaluable
patients). The most common reasons for death
were multi-organ failure and septic shock
[n = 17 (9.7%) and n = 10 (5.7%), respectively].
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A flow diagram detailing patient disposition is
presented in Fig. 2.
Demographic data and clinical characteris-
tics are summarised in Table 1. The mean age
was 67 years and most patients were male. The
mean duration of stay in the ICU was 6.3 days.
A total of 132 (75%) patients had a Candida
score C 3 and 169 (96.0%) had sepsis. In total,
99 patients (56.3%) had concomitant infections
and 167 (94.9%) were receiving concomitant
antibiotic treatment. The median number of
days that patients were in the ICU before initi-
ation of antifungal treatment was 5 days (in-
terquartile range, 1–12 days).
Empirical Antifungal Treatment
In patients with available data (n = 116), the
mean (SD) duration of antifungal treatment was
21.72 (17.50) days. For participants who
received C 1 follow-up visit (n = 167), the
microbiological response was non-evaluable for
the majority of patients (n = 122/167, 73.1%).
According to clinical criteria, 34 (20.4%) of
patients were cured, 76 (45.5%) were improved
and 57 (34.1%) experienced treatment failure.
Candida eradication was achieved in 28/167
(16.8%) patients, but persisted (at the end of
antifungal treatment) in 17/167 (10.2%)
patients.
Primary End Point
Rates of detection of Candida infection were
similar for blood culture and serum PCR
[n = 14/175 (8.0%) with blood culture and
n = 16/175 (9.1%) with serum PCR]. C. albicans
was the most common pathogen and was
detected with a greater frequency with serum
PCR (14/16, 87.5%) than with blood culture (8/
14, 57.1%). Other pathogens that were detected
using both techniques were C. glabrata (12.5%
and 42.9%, respectively) and C. krusei (12.5%
and 7.1%, respectively). C. tropicalis and C.
parasilopsis were detected in one sample each
using blood culture.
Concordance rates and quality indices for
the results of blood culture versus serum PCR
are shown in Table 2. The sensitivity of serum
PCR relative to blood culture was 21.4% and the
specificity was 91.9%; the PPV was 18.8% and
the NPV was 93.1%, while the PPTP and NPTP
were 18.8% and 6.9%, respectively, indicating
that the concordance of serum PCR using blood
culture as a reference was very low, as confirmed
by the kappa value (0.125) (Table 2).
Secondary End Points
Thirty-two patients had positive results for
Candida spp. in the abdominal fluid. The most
common species were C. albicans [n = 18
(56.3%)] and C. glabrata [n = 9 (28.1%)].
Concordance rates and quality indices for
the results for serum PCR versus abdominal
fluid samples are also shown in Table 2. The
sensitivity and specificity of serum PCR relative
to abdominal fluid were 31.3% and 83.0%,
respectively. The PPV and NPV were 15.6% and
92.3%, respectively; PPTP was 17.0% and NPTP
was 7.7%. The kappa index was 0.100, also
indicating a low rate of concordance between
serum PCR and abdominal fluid samples.
When the results of serum PCR versus the
composite measure of blood culture plus
Fig. 2 Flow chart of the study population
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abdominal fluid were examined, the quality
indices remained comparable (sensitivity
15.8%; specificity 92.7%; PPV 37.5%; NPV
79.9%). The kappa index was 0.107, again
indicating a very low rate of concordance
between serum PCR and the composite
measure.
Table 1 Demographics and clinical characteristics at
baseline
Patient characteristic Mean (SD),
unless
specified
(N = 176)
Gender, n (%)
Male 115 (65.3)
Female 61 (34.7)
Age (years) 66.6 (12.7)
BMI (kg/m2) 28.0 (6.4)
Reason for ICU admission, n (%)
Medical 88 (50.0)
Surgical 88 (50.0)
Abdominal 81 (46.0)
Chest 4 (2.3)
Cardiovascular 4 (2.3)
Orthopaedic and trauma surgery 1 (0.6)
Other 2 (1.1)
Duration of ICU stay (days) 6.3 (9.9)
Candida score 3.10 (1.16)
Patients with Candida score, n (%)
\ 3 44 (25.0)
3 56 (31.8)
4 67 (38.1)
5 9 (5.1)
Patients with sepsis, n (%) 169 (96.0)
Severe 43 (24.4)
Septic shock 103 (58.5)
Patients considered at high risk, n (%)
Candida score C 3 132 (75.0)
Serious sepsis (2 points) 147 (83.5)
Prior abdominal surgery (1 point) 116 (65.9)
Parenteral nutrition (1 point) 108 (61.4)
Multiple colonisation (1 point) 27 (15.3)
Table 1 continued
Patient characteristic Mean (SD),
unless
specified
(N = 176)
Sepsis in patients with C 3 risk factors 163 (92.6)
Serious acute pancreatitis 24 (13.6)
Extrarenal depuration 56 (31.8)
Broad-spectrum antibiotics[ 7 days 105 (59.7)
Major abdominal surgery 116 (65.9)
Admission to ICU[ 15 days 51 (29.0)
Parenteral nutrition 109 (61.9)
Central venous catheter 162 (92.0)
Colonisation in 2 or more locations 27 (15.3)
Candiduria 21 (11.9)
APACHE on admission[ 15 120 (68.2)
Diabetes mellitus 39 (22.2)
Major burns (serious burns) 0 (0)
Sepsis in patients with
immunosuppression
36 (20.5)
Neutropenia 5 (2.8)
Haematological disease 4 (2.3)
Solid organ or bone marrow
transplantation
9 (5.1)
Treatment with immunosuppresive
drugs, chemotherapy agents or
monoclonal antibodies
29 (16.5)
Human immunodeficiency virus 5 (2.8)
BMI body mass index, ICU intensive care unit, SD stan-
dard deviation
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Risk Factors for Invasive Candidiasis
Results of the analysis of the relationship
between the presence of invasive candidiasis
and patient risk factors are summarised in
Table 3. The only significant relationships were
between the presence of invasive candidiasis as
determined using abdominal fluid/the com-
posite measure and a candidiasis score C 3 (both
P = 0.006).
According to the logistic regression analyses
(Table 4), patients with a Candida score C 3
were seven times more likely to present with
invasive candidiasis than those with a lower
Candida score when assessed by blood culture,
but this result was non-significant (P = 0.100).
They were also 4.15 times more likely present
with invasive candidiasis when assessed using
the composite measure (P = 0.030). When
assessed using serum PCR, none of the three risk
factors influenced the probability of being pos-
itive for Candida spp. (Table 4).
Patient risk factors that were positively but
not statistically significantly associated with the
presence of invasive candidiasis according to
blood culture results, using the adjusted binary
logistic regression model, were abdominal sur-
gery (OR 4.342; P = 0.068) and an ICU
stay[15 days (OR 2.560, P = 0.090) (Table 5).
There was also a 44% relative reduction in the
risk of invasive candidiasis in non-immuno-
suppressed versus immunosuppressed patients
(OR 0.556), but this was not statistically signif-
icant (P = 0.419) (Table 5).
DISCUSSION
The primary objective of this study was to
examine the concordance between the results
for serum PCR and blood culture for the
Table 2 Quality indices for serum PCR, blood culture, abdominal fluid and the composite measure in patients with
suspected invasive candidiasis
Parameter PCR vs. blood
culture (n = 175)
PCR vs. abdominal
fluid (n = 175)
PCR vs. composite measure
(blood culture and
abdominal fluid) (n = 175)
True positive, n 3 5 6
False negative, n 11 27 32
False positive, n 13 11 10
True negative, n 148 132 127
Sensitivity, % (95% CI) 21.4 (0.0–42.9) 31.3 (8.5–54.0) 15.8 (4.2–27.4)
Specificity, % (95% CI) 91.9 (87.7–96.1) 83.0 (77.2–88.9) 92.7 (88.3–97.1)
PPV, % (95% CI) 18.8 (0.0–37.9) 15.6 (3.0–28.2) 37.5 (13.8–61.2)
NPV, % (95% CI) 93.1 (89.1–97.0) 92.3 (87.9–96.7) 79.9 (73.6–86.1)
PLR, ratio (95% CI) 2.65 (0.86–8.22) 2.03 (0.37–2.68) 2.16 (0.84–5.57)
NLR, ratio (95% CI) 0.85 (0.63–1.17) 0.91 (0.88–1.13) 0.91 (0.75–1.10)
PPTP, % (95% CI) 18.8 (0.0–37.9) 17.0 (4.0–20.0) 37.5 (13.8–61.2)
NPTP, % (95% CI) 6.9 (3.0–10.9) 7.7 (3.3–10.0) 20.1 (13.9–26.3)
Kappa index (95% CI) 0.125 (0.00–0.33) 0.100 (0.00–0.26) 0.107 (0.00–0.26)
CI confidence interval, NLR negative likelihood ratio, NPTP negative post-test probability, NPV negative predictive value,
PCR polymerase chain reaction, PLR positive likelihood ratio, PPTP positive post-test probability, PPV positive predictive
value
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detection of Candida spp. in patients admitted
to ICUs in Spain and in whom empirical anti-
fungal treatment was initiated because of sus-
pected invasive candidiasis. Although a meta-
analysis of studies evaluating PCR diagnosis for
invasive candidiasis was published in 2011 [36],
the patient populations assessed in this study
were highly heterogeneous in terms of country
of origin, age, underlying conditions, etc. In
contrast, the current study provides informa-
tion on a specific group of patients from Spain.
It is important determine the issues that lead
physicians to initiate antifungal therapy [39]
and to perform PCR simultaneously with blood
culture to avoid storage problems.
In this study, the rates of Candida detection
in blood samples were low, whether using
serum PCR (16/175, 9.1%) or blood culture (14/
175, 8.0%). Candida spp. appeared to be more
readily detected in the abdominal fluid (32/49,
65.3%). As could be expected, C. albicans was
the most frequently detected species, although
C. glabrata, C. krusei, C. tropicalis and C. parap-
silosis were also identified. These five species
represent the most common Candida pathogens
[20, 30].
The sensitivity of serum PCR relative to
blood culture for the detection of Candida spp.
was 21.4%. While the results for PCR relative to
abdominal fluid were marginally higher
(31.3%), the sensitivity of serum PCR relative to
the composite measure (Candida positivity in
blood culture or abdominal fluid) decreased
even further (15.8%) (Table 2).
While the specificity and NPV values for PCR
obtained in the current study were similar to
those previously reported in other studies
[25, 36, 40], the sensitivity and PPV values
achieved (Table 2) were much lower overall.
This may be due to the use of serum samples for
Table 3 Relationship between presence of invasive candidiasis and patient risk factors
Candida score ‡ 3 Sepsis with ‡ 3 risk factors Sepsis in patients with
immunosuppression
Yes No Pa Yes No Pa Yes No Pa
n % n % n % n % n % n %
Serum PCR
Negative 119 90.8 40 90.9 0.989 147 90.7 12 92.3 [ 0.05 35 97.2 124 89.2 [ 0.05
Positive 12 9.2 4 9.1 15 9.3 1 7.7 1 2.8 15 10.8
Blood culture
Negative 118 90.1 43 97.7 0.106 149 92.0 12 92.3 [ 0.05 33 91.7 128 92.1 [ 0.05
Positive 13 9.9 1 2.3 13 8.0 1 7.7 3 8.3 11 7.9
Abdominal fluid
Negative 101 77.1 42 95.5 0.006 131 80.9 12 92.3 [ 0.05 33 91.7 110 79.1 [ 0.05
Positive 30 22.9 2 4.5 31 19.1 1 7.7 3 8.3 29 20.9
Blood
culture ? abdominal
fluid
Negative 96 73.3 41 93.2 0.006 125 77.2 12 92.3 [ 0.05 32 88.9 105 75.5 [ 0.05
Positive 35 26.7 3 6.8 37 22.8 1 7.7 4 11.1 34 24.5
PCR polymerase chain reaction
a Chi-squared test
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our PCR assays rather than whole blood,
according to each site’s usual practice; greater
sensitivity has been reported when PCR is per-
formed in whole-blood samples [36; the CAN-
DINEO Study [40].
The results from our analyses showed a very
low concordance rate between the results of
serum PCR and blood culture (kappa index:
0.125). The degree of concordance was not
enhanced by using the composite measure,
since the kappa index for serum PCR versus the
composite measure was 0.107, again indicating
a very low degree of concordance between
serum PCR and the other diagnostic techniques
used in this study.
Logistic regression analyses of the risk factors
that, in clinical terms, may be considered to
contribute to the probability of developing a
Candida infection indicated a direct relation-
ship between a Candida score[3 and a higher
probability of invasive candidiasis (as diagnosed
using blood culture or the composite measure).
None of the other risk factors showed a partic-
ular association with the risk of developing
invasive candidiasis.
An additional binary logistic regression
model was used to determine which factors are
most related to the presence of candidiasis,
according to the blood culture result. Abdomi-
nal surgery and a longer ICU stay ([15 days)
Table 4 Logistic regression models for risk factors
Risk factor Effect OR 95% CI P
Candida infection according to blood culture
Candida score C 3 Yes vs. no 7.00 (0.69–71.31) 0.100
Sepsis with C 3 risk factors Yes vs. no 0.51 (0.04–5.93) 0.594
Sepsis in patients with immunosuppression Yes vs. no 1.62 (0.37–7.03) 0.521
Candida infection according to serum PCR
Candida score C 3 Yes vs. no 0.71 (0.20–2.49) 0.588
Sepsis with C 3 risk factors Yes vs. no 0.39 (0.03–5.26) 0.481
Sepsis in patients with immunosuppression Yes vs. no 0.14 (0.01–1.77) 0.128
Candida infection according to blood culture ? abdominal fluid
Candida score C 3 Yes vs. no 4.15 (1.15–14.98) 0.030
Sepsis with C 3 risk factors Yes vs. no 1.36 (0.14–12.93) 0.789
Sepsis in patients with immunosuppression Yes vs. no 0.62 (0.19–2.05) 0.432
CI confidence interval, OR odds ratio, PCR polymerase chain reaction
Table 5 Risk factors associated with the presence of invasive candidiasis according to blood culture (adjusted binary logistic
regression model with a bilateral significance level of 0.10, Chi-squared test)
Risk factor Effect OR 95% CI P
Candida infection according to blood culture
Abdominal surgery Yes vs. no 4.342 (0.898–20.998) 0.068
Admission to ICU [ 15 days vs. B 15 days 2.560 (0.793–8.263) 0.090
Sepsis to patients with some immunosuppression criterion Yes vs. no 0.556 (0.134–2.308) 0.419
CI confidence interval, ICU intensive care unit, OR odds ratio
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showed a positive trend towards being risk fac-
tors for the presence of Candida spp. in blood
cultures. These findings are consistent with
previous studies, which have also found that
abdominal surgery and length of stay at the ICU
are associated with higher risk of invasive can-
didiasis [1, 41]. Conversely, we cannot explain
why a very low concordance was found between
blood culture and PCR; it may be necessary to
perform PCR at the same time as blood culture.
The apparent lack of relationship between
risk factors and the presence of invasive can-
didiasis using PCR is somewhat surprising,
especially when this technique has proved to be
very sensitive in similar ICU settings [25].
However, in another study the diagnostic
accuracy of PCR was also low because the tests
were performed in frozen samples [40]; this
factor may be applicable to our study because of
the freezing of samples prior to dispatch to the
Reference Centre. In addition, there was no
significant relationship between invasive can-
didiasis (as assessed using blood culture) and a
number of known risk factors. This may also be
attributable to the low sensitivity of blood cul-
tures to diagnose Candida infections and the
broad definition of a ‘high-risk’ population.
Patients with just one of three positive blood
cultures might have shown a negative PCR
because of a low burden of Candida spp. Like-
wise, regarding the origin of candidaemia,
abdominal fluid from a peritoneal catheter may
present a higher Candida burden than an intra-
abdominal infection and therefore diminish the
sensitivity of PCR. Difficulties with distin-
guishing Candida colonisation from intra-ab-
dominal invasive candidiasis may contribute to
the low sensitivity of PCR in some patients [30].
Due to the non-interventional nature of this
study, all patient examinations and follow-up
visits were performed in line with the investi-
gators’ usual clinical practice. The low cure rate
is of note, but it is not possible to speculate on
the reasons for this as information relating to
treatment strategies is not available. The lack of
use of follow-up PCR is also notable, and the
possible reasons for this may include discharge
of patients to other units and therefore loss to
follow-up or improvement of their clinical
condition and therefore no additional samples
or investigations were needed.
In a high proportion of cases, a follow-up
blood culture was not conducted, i.e. the
physicians in this study appeared to rely on
signs and symptoms to determine whether the
Candida infection had resolved. Other recent
studies that have evaluated PCR as a diagnostic
tool for invasive candidiasis have reported
conflicting results [25, 40, 42]. In a Spanish
study amongst critically ill patients admitted to
the ICU, PCR appeared to have a high sensitiv-
ity (96.3%), specificity (97.3%) and strong pos-
itive predictive value (92.8%), especially in
patients with deep-seated disease (sensitivity
90.9% versus 45.4% for blood culture) [25], and
therefore the authors concluded that PCR may
be a useful test for confirming a diagnosis of
invasive candidiasis [25]. However, in our study
of high-risk patients, the incidence of candi-
daemia was strikingly lower than in the previ-
ous study [25]. Similarly, in another recent
Spanish study, PCR had a low discriminating
capacity (sensitivity 84.00%; PPV 26.9%), whe-
ther used alone or in combination with other
antibody-based diagnostic tests [40]. In the
study by Nguyen et al. [42], Candida PCR testing
was more sensitive than blood cultures among
patients with deep-seated candidiasis (88% ver-
sus 17%, respectively), and it significantly
enhanced the ability of blood culture to detect
invasive candidiasis by increasing overall sensi-
tivity to 98% when used in combination with
blood culture [42].
Nonetheless, significant shortcomings for
PCR testing still remain, for instance, a rela-
tively low sensitivity because of the low quan-
tity of Candida cells in the blood [1], sample
susceptibility to contamination [25] and other
issues that need to be overcome before it can be
used routinely and effectively in clinical prac-
tice (e.g. the lack of a standardised assay) [40].
Also, the lack of commercially available meth-
ods that are easy-to-use is still limiting [1]; dif-
ferent methodologies between centres
performing these assays may also affect the
consistency of clinical data which are
generated.
Another limitation of the study was that
information on patients who failed screening
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was not collected; for this reason, the possibility
of selection bias cannot be excluded. Due to its
observational nature, additional limitations of
this study may have included variations in
physicians’ clinical practice among all 27 par-
ticipating centres. In addition, a second PCR
that might provide information as to whether
the initial negative results were truly negative
was performed in very few patients. Further-
more, a number of pre-specified secondary end
points (such as the prognostic value and diag-
nostic sensitivity of serum PCR in invasive
candidiasis) were not assessed as planned
because of low patient numbers or a low
prevalence of invasive candidiasis in our sam-
ples. It would also be interesting to evaluate
whether the outcomes of patients diagnosed by
PCR and blood culture differ, but this was
beyond the scope of the current study.
CONCLUSIONS
In this observational, prospective, multicentre
study amongst critically ill patients at a high
risk of invasive candidiasis who had been
admitted to an ICU, there was a low rate of
concordance between serum PCR and blood
culture, and serum PCR and culture of abdom-
inal fluid samples, for the diagnosis of Candida
infections. Thus, the PCR methodology used in
the current study would not provide a clear
diagnostic advantage in these patients. Within
this patient population, there was a direct and
statistically significant association between a
Candida score[ 3 and a higher probability of
invasive candidiasis. Other evidence has sub-
stantiated the need for rapid and accurate
methods to detect Candida spp., but this study
highlights the importance of refining and vali-
dating such tests as well as establishing the risk
factors for identification of critically ill patients
who require early therapeutic intervention.
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